Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
18.20
-0.06 (-0.33%)
Oct 26, 2026, 9:39 AM EDT - Market open
Vor Biopharma Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Vor Biopharma stock has a consensus rating of "Strong Buy" and an average price target of $39. The average 1-year stock price forecast is 114.29% higher than the current stock price, while the lowest is $27 (+48.35%) and the highest is $50 (+174.73%).
Price Target: $39 (+114.29%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Vor Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 8 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Oct 21, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $30 | Buy | Maintains | $30 | +64.84% | Oct 16, 2026 |
| Citi | Citi | Buy Maintains $50 | Buy | Maintains | $50 | +174.73% | Oct 15, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $40 | Buy | Maintains | $40 | +119.78% | Sep 28, 2026 |
| Jefferies | Jefferies | Buy Maintains $48 | Buy | Maintains | $48 | +163.74% | Sep 9, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-6.89
from -70.50
EPS Next Year
-3.67
from -6.89
EPS and Forward PE are based on non-GAAP adjusted numbers.